Interleukin-35 inhibits human umbilical vein endothelial cell injury induced by sera from pre-eclampsia patients by up-regulating S100A8 protein expression

The expression of Sirt1/FoxO1 pathway in the placenta of patients with preeclampsia and its connection with prognosis

This study aimed to analyse the expression of Sirt1/FoxO1 pathway in the placenta of patients with preeclampsia (PE). Clinical data of 111 PE patients were retrospectively analysed and divided into mild group (n = 61) and severe group (n = 50) according to the severity of condition. Another 45 healthy mothers were selected as healthy group. The value of Sirt1/FoxO1 pathway-related proteins in predicting prognosis of PE patients was analysed. The severe group had higher Sirt1 and lower FoxO1 protein expressions than the mild and healthy groups (p < 0.05). Sirt1 protein expression was positively correlated with ROS, LHP, NOX4, IL-1β, IL-6, HMGB1, CRP, VCAM-1, Caspase-3, Fas, Apaf-1 and ET-1 in PE patients (r > 0, p < 0.05), while FoxO1 protein expression was negatively correlated with these indices (r < 0, p < 0.05). Sirt1 protein expression was negatively correlated with SOD, CAT, GSH-Px, Bcl-2, Mcl-2, P57_kip2 and NO (r < 0, p < 0.05), while FoxO1 protein expression was positively correlated with these indices (r > 0, p < 0.05). The expression of Sirt1/FoxO1 pathway related proteins was abnormal in placenta of PE patients, and was closely related to the expression of oxidative stress, inflammatory response, endothelial damage factors and apoptotic molecules.IMPACT STATEMENTWhat is already known on this subject? The Sirt1/FoxO1 pathway is abnormally expressed in the placenta of preeclampsia patients, with Sirt1 protein expression up-regulated and FoxO1 protein expression down-regulated, both of which are closely related to the expression of oxidative stress, inflammatory response, endothelial damage factors and apoptotic molecules in the placenta of preeclampsia patients.What do the results of this study add? The results of this study add to the knowledge about the role of the Sirt1/FoxO1 pathway in the pathogenesis of preeclampsia.What are the implications of these findings for clinical practice and/or further research? These findings provide a basis for predicting poor pregnancy outcomes in patients with preeclampsia in clinical practice.

Co-culture with chorionic villous mesenchymal stem cells promotes endothelial cell proliferation and angiogenesis via ABCA9-AKT pathway

Human chorionic villous mesenchymal stem cells (CV-MSCs) are a promising and effective therapeutic option for tissue injury. Vascular dysfunction during pregnancies is significantly involved in the pathogenesis of preeclampsia (PE). This work aims to investigate how CV-MSCs regulate the function of vascular endothelial cells. In this study, RNA-seq analysis was used to examine the changes in HUVECs treated with CV-MSC conditioned medium (CM). We examined the levels of ABCA9 and AKT signaling in human umbilical vein endothelial cells (HUVECs) by immunohistochemistry, western blotting, and qRT-PCR assays. CCK-8, colony formation, and tube formation assays were used to understand the role of ABCA9 in HUVEC proliferation and angiogenesis mediated by CV-MSCs. The CV-MSC treatment significantly enhanced the HUVEC proliferation and angiogenesis. Furthermore, a significant increase in the ABCA9 expression and AKT pathway activation was observed in CV-MSCs -treated HUVECs. Consistent with these findings, ABCA9 overexpression exhibited the same proliferation-and angiogenesis-promoting effect in HUVECs as induced by CV-MSC CM, also accompanied the AKT signaling activation. In addition, inhibition of ABCA9 inactivated the AKT signaling in HUVECs and reduced the HUVEC proliferation and angiogenesis. Importantly, the elevation of proliferation and angiogenesis induced by ABCA9 overexpression in HUVECs could be reversed by AKT pathway inhibition. Our results suggest that ABCA9-dependent AKT signaling activation mediated by CV-MSCs could promote HUVEC proliferation and angiogenesis.